SCHEMBL4818308

SCHEMBL4818308

O=CN(O)C(CCc1ccccc1)CS(=O)(=O)N1CCN(c2ccc(Cl)cn2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP7 P09237 1/20 0.60
MMP13 P45452 4/20 0.57
CYP3A4 P08684 3/20 0.57
MMP14 P50281 3/20 0.43
ADAMTS4 O75173 2/20 0.43
KCNH2 Q12809 2/20 0.43
RORC P51449 3/20 0.41
MMP1 P03956 1/20 0.38
ME2 P23368 3/20 0.38
ME1 P48163 3/20 0.38
ME3 Q16798 3/20 0.38
DRD2 P14416 2/20 0.37
DRD4 P21917 2/20 0.37
HTR1A P08908 1/20 0.37
HTR2A P28223 1/20 0.37
HTR2C P28335 1/20 0.37
HTR7 P34969 1/20 0.37
DRD3 P35462 1/20 0.37
TMEM97 Q5BJF2 1/20 0.37
SIGMAR1 Q99720 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14252766 0.95 MMP7 (0.65) MMP7MMP13CYP3A4MMP14ADAMTS4
SCHEMBL14252764 0.91 MMP7 (0.59) MMP7MMP13CYP3A4MMP14ADAMTS4
SCHEMBL5883099 0.89 MMP7 (0.72) MMP7MMP13CYP3A4MMP14ADAMTS4
SCHEMBL5883710 0.89 MMP7 (0.72) MMP7MMP13CYP3A4MMP14ADAMTS4
SCHEMBL5883961 0.89 MMP7 (0.72) MMP7MMP13CYP3A4MMP14ADAMTS4
SCHEMBL14252767 0.89 MMP7 (0.62) MMP7MMP13CYP3A4MMP14ADAMTS4
SCHEMBL12463859 0.87 MMP7 (0.59) MMP7MMP13CYP3A4MMP14ADAMTS4
SCHEMBL14252763 0.87 MMP7 (0.61) MMP7MMP13CYP3A4MMP14ADAMTS4
SCHEMBL14252770 0.87 MMP7 (0.53) MMP7MMP13CYP3A4MMP14ADAMTS4
SCHEMBL5884462 0.86 MMP7 (0.61) MMP7MMP13CYP3A4MMP14ADAMTS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7342020-B2 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) ASTRAZENECA AB (SE) 2008-03-11 US disclosed
US-7342020-B2 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) ASTRAZENECA AB (SE) 2008-03-11 US disclosed
US-7342020-B2 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) ASTRAZENECA AB (SE) 2008-03-11 US disclosed
EP-1109787-B1 ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) ASTRAZENECA AB (SE) 2006-05-17 EP disclosed
US-20040171641-A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) ASTRAZENECA AB (SE) 2004-09-02 US disclosed
US-6734184-B1 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) ASTRAZENECA AB (SE) 2004-05-11 US disclosed
EP-1109787-A1 ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) AstraZeneca AB (SE) 2001-06-27 EP disclosed
WO-2000012478-A1 ARYLPIPERAZINES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS (MMP) ASTRAZENECA AB (SE) 2000-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171641-A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (MMP) MMP13, MMP25, MMP3 MMP7 17/4885MMP13 1/4885CYP3A4 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.